开云app官网登录入口网页版-官方正版

#mCRPC#

17篇内容 | 1495人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2207248, encodeId=901d220e2489e, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a> <a href='/topic/show?id=0de5290588c' target=_blank style='color:#2F92EE;'>#免疫检查点抑制剂#</a> <a href='/topic/show?id=641e1139ea8' target=_blank style='color:#2F92EE;'>#mCRPC#</a>, objectTitle=CLIN CANCER RES | 免疫检查点抑制剂治疗晚期转移性去势抵抗性前列腺癌的II期IMPACT试验, objectType=article, longId=828024, objectId=0f4e82802409, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240529/1716959363021_6145188.png, objectUrl=/article/show_article.do?id=0f4e82802409, replyNumber=0, likeNumber=84, createdTime=2024-05-29, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=0f4e82802409, moduleTitle=CLIN CANCER RES | 免疫检查点抑制剂治疗晚期转移性去势抵抗性前列腺癌的II期IMPACT试验, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=0f4e82802409)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2164671, encodeId=723d21646e1eb, content= <a href='/topic/show?id=c1d6150547b' target=_blank style='color:#2F92EE;'>#Ra-223#</a>治疗的 <a href='/topic/show?id=641e1139ea8' target=_blank style='color:#2F92EE;'>#mCRPC#</a>患者中，<a href='/topic/show?id=fd1910e21591' target=_blank style='color:#2F92EE;'>#骨代谢生物标志物#</a> (BMB) 的预后价值。 , objectTitle=Eur Urol Oncol：镭-223治疗转移去势抵抗性前列腺癌患者的骨代谢生物标志物和生存期的前瞻性评估： PRORADIUM研究, objectType=article, longId=797596, objectId=de42e975968e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301024/1698113695977_1935437.jpg, objectUrl=/article/show_article.do?id=de42e975968e, replyNumber=0, likeNumber=147, createdTime=2023-10-24, rootId=0, userName=litao2022, userId=1ff65466529, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=de42e975968e, moduleTitle=Eur Urol Oncol：镭-223治疗转移去势抵抗性前列腺癌患者的骨代谢生物标志物和生存期的前瞻性评估： PRORADIUM研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=de42e975968e)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=2161856, encodeId=8bc82161856a2, content=<a href='/topic/show?id=41f54454653' target=_blank style='color:#2F92EE;'>#奥拉帕利#</a>联合<a href='/topic/show?id=de489e856c6' target=_blank style='color:#2F92EE;'>#阿比特龙#</a>治疗<a href='/topic/show?id=a17393408d0' target=_blank style='color:#2F92EE;'>#转移性去势抵抗性前列腺癌#</a>（<a href='/topic/show?id=641e1139ea8' target=_blank style='color:#2F92EE;'>#mCRPC#</a>）结果公布（<a href='/topic/show?id=60fc10686398' target=_blank style='color:#2F92EE;'>#PROpel研究#</a>），在放射学<a href='/topic/show?id=383d5916654' target=_blank style='color:#2F92EE;'>#无进展生存#</a> (rPFS) 方面具有<a href='/topic/show?id=119ee8941fa' target=_blank style='color:#2F92EE;'>#统计学意义#</a>和<a href='/topic/show?id=1a12228169a' target=_blank style='color:#2F92EE;'>#临床意义#</a>的改善显著，但是最近又报道了<a href='/topic/show?id=3c34691e189' target=_blank style='color:#2F92EE;'>#生活质量#</a>方面并没有变化，后续报道OS也没有统计学显著性区别，看来这也是一个隐忧，临床上值得不值得应用？, objectTitle=NEJM Evid：奥拉帕利联合阿比特龙治疗转移性前列腺癌结果公布（PROpel研究）, objectType=article, longId=729571, objectId=1e09e2957129, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20220608/d267bfd33c844ab48ad9dc551f5dcd96.jpg, objectUrl=/article/show_article.do?id=1e09e2957129, replyNumber=0, likeNumber=107, createdTime=2023-10-10, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=1e09e2957129, moduleTitle=NEJM Evid：奥拉帕利联合阿比特龙治疗转移性前列腺癌结果公布（PROpel研究）, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1e09e2957129)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1555946, encodeId=6fb7155594633, content=<a href='/topic/show?id=641e1139ea8' target=_blank style='color:#2F92EE;'>#mCRPC#</a>, objectTitle=Target Oncol:真实世界评估阿比特龙+泼尼松或泼尼松龙(AAP)一线或二线治疗转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性, objectType=article, longId=299289, objectId=97bb29928916, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97bb29928916, replyNumber=0, likeNumber=101, createdTime=2022-02-22, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97bb29928916, moduleTitle=Target Oncol:真实世界评估阿比特龙+泼尼松或泼尼松龙(AAP)一线或二线治疗转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=97bb29928916)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555945, encodeId=e81e155594599, content=<a href='/topic/show?id=641e1139ea8' target=_blank style='color:#2F92EE;'>#mCRPC#</a>, objectTitle=Eur J Cancer：Nivolumab联合多西他赛治疗未经化疗的转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性, objectType=article, longId=221438, objectId=433422143891, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=433422143891, replyNumber=0, likeNumber=127, createdTime=2021-12-04, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=433422143891, moduleTitle=Eur J Cancer：Nivolumab联合多西他赛治疗未经化疗的转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=433422143891)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555944, encodeId=6f3615559441b, content=<a href='/topic/show?id=641e1139ea8' target=_blank style='color:#2F92EE;'>#mCRPC#</a>, objectTitle=Lancet Oncol：阿帕鲁胺联合阿比特龙-泼尼松可明显改善mCRPC患者的生存预后, objectType=article, longId=218148, objectId=fdff218148d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdff218148d4, replyNumber=0, likeNumber=85, createdTime=2021-10-07, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdff218148d4, moduleTitle=Lancet Oncol：阿帕鲁胺联合阿比特龙-泼尼松可明显改善mCRPC患者的生存预后, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=fdff218148d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555943, encodeId=3ec8155594362, content=<a href='/topic/show?id=641e1139ea8' target=_blank style='color:#2F92EE;'>#mCRPC#</a>, objectTitle=EU：评估哪些mCRPC患者更适合阿比特龙的模型, objectType=article, longId=217639, objectId=674a21e639d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=674a21e639d1, replyNumber=0, likeNumber=87, createdTime=2021-09-26, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=674a21e639d1, moduleTitle=EU：评估哪些mCRPC患者更适合阿比特龙的模型, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=674a21e639d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555942, encodeId=b7a3155594279, content=<a href='/topic/show?id=641e1139ea8' target=_blank style='color:#2F92EE;'>#mCRPC#</a>, objectTitle=Clin Cancer Res：遗憾！阿特珠单抗+镭-223联合方案未能给mCRPC患者带来额外的临床效益, objectType=article, longId=216703, objectId=fd7e216e0320, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd7e216e0320, replyNumber=0, likeNumber=78, createdTime=2021-09-06, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd7e216e0320, moduleTitle=Clin Cancer Res：遗憾！阿特珠单抗+镭-223联合方案未能给mCRPC患者带来额外的临床效益, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=fd7e216e0320)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555941, encodeId=193a155594187, content=<a href='/topic/show?id=641e1139ea8' target=_blank style='color:#2F92EE;'>#mCRPC#</a>, objectTitle=Eur J Cancer：耄耋之年mCRPC患者采用恩杂鲁胺治疗的效果优于醋酸阿比特龙, objectType=article, longId=212999, objectId=791f2129998e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=791f2129998e, replyNumber=0, likeNumber=114, createdTime=2021-06-22, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=791f2129998e, moduleTitle=Eur J Cancer：耄耋之年mCRPC患者采用恩杂鲁胺治疗的效果优于醋酸阿比特龙, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=791f2129998e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555940, encodeId=27001555940f2, content=<a href='/topic/show?id=641e1139ea8' target=_blank style='color:#2F92EE;'>#mCRPC#</a>, objectTitle=ASCO GU 2021：nmCRPC接受恩扎鲁胺治疗患者中PSA下降深度与生存结果密切相关（PROSPER试验）, objectType=article, longId=207162, objectId=89d220e162b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89d220e162b5, replyNumber=0, likeNumber=82, createdTime=2021-02-17, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89d220e162b5, moduleTitle=ASCO GU 2021：nmCRPC接受恩扎鲁胺治疗患者中PSA下降深度与生存结果密切相关（PROSPER试验）, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=89d220e162b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555939, encodeId=fe1f1555939c9, content=<a href='/topic/show?id=641e1139ea8' target=_blank style='color:#2F92EE;'>#mCRPC#</a>, objectTitle=Onvansertib能够克服Zytiga耐药性并为mCRPC患者提供临床益处, objectType=article, longId=188104, objectId=396c1881042f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=396c1881042f, replyNumber=0, likeNumber=83, createdTime=2020-02-16, rootId=0, userName=liuquanmn, userId=d48314676153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=396c1881042f, moduleTitle=Onvansertib能够克服Zytiga耐药性并为mCRPC患者提供临床益处, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=396c1881042f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555938, encodeId=2bb415559389b, content=<a href='/topic/show?id=641e1139ea8' target=_blank style='color:#2F92EE;'>#mCRPC#</a>, objectTitle=Trovagene在ASCO-GU会议上介绍了Onvansertib与Zytiga联合治疗mCRPC的II期研究, objectType=article, longId=160409, objectId=dada1604094f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dada1604094f, replyNumber=0, likeNumber=75, createdTime=2019-02-20, rootId=0, userName=liuquanmn, userId=d48314676153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dada1604094f, moduleTitle=Trovagene在ASCO-GU会议上介绍了Onvansertib与Zytiga联合治疗mCRPC的II期研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=dada1604094f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555937, encodeId=a217155593e9e, content=<a href='/topic/show?id=641e1139ea8' target=_blank style='color:#2F92EE;'>#mCRPC#</a>, objectTitle=HPN424治疗转移性去势抵抗性前列腺癌（mCRPC）的I期临床试验, objectType=article, longId=146129, objectId=b5731461296f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5731461296f, replyNumber=0, likeNumber=72, createdTime=2018-08-09, rootId=0, userName=liuquanmn, userId=d48314676153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5731461296f, moduleTitle=HPN424治疗转移性去势抵抗性前列腺癌（mCRPC）的I期临床试验, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=b5731461296f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555936, encodeId=9eb5155593646, content=<a href='/topic/show?id=641e1139ea8' target=_blank style='color:#2F92EE;'>#mCRPC#</a>, objectTitle=Eur Urol：mCRPC患者外周全血中的AR-V7预测治疗反应。, objectType=article, longId=110753, objectId=4a71110e53ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a71110e53ef, replyNumber=0, likeNumber=111, createdTime=2017-08-26, rootId=0, userName=liuquanmn, userId=d48314676153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a71110e53ef, moduleTitle=Eur Urol：mCRPC患者外周全血中的AR-V7预测治疗反应。, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=4a71110e53ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555935, encodeId=8617155593511, content=<a href='/topic/show?id=641e1139ea8' target=_blank style='color:#2F92EE;'>#mCRPC#</a>, objectTitle=J Clin Oncol：巴他赛 vs 多西他赛一线治疗mCRPC 孰优孰劣？, objectType=article, longId=107937, objectId=e9d610e937e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e9d610e937e0, replyNumber=0, likeNumber=0, createdTime=2017-08-08, rootId=0, userName=liuquanmn, userId=d48314676153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e9d610e937e0, moduleTitle=J Clin Oncol：巴他赛 vs 多西他赛一线治疗mCRPC 孰优孰劣？, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=e9d610e937e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555934, encodeId=836c1555934a3, content=<a href='/topic/show?id=641e1139ea8' target=_blank style='color:#2F92EE;'>#mCRPC#</a>, objectTitle=J Clin Oncol:卡巴他赛 vs 多西他赛一线治疗mCRPC 孰优孰劣？, objectType=article, longId=107932, objectId=449c10e9323f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=449c10e9323f, replyNumber=0, likeNumber=94, createdTime=2017-08-08, rootId=0, userName=liuquanmn, userId=d48314676153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=449c10e9323f, moduleTitle=J Clin Oncol:卡巴他赛 vs 多西他赛一线治疗mCRPC 孰优孰劣？, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=449c10e9323f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555933, encodeId=e3a61555933f3, content=<a href='/topic/show?id=641e1139ea8' target=_blank style='color:#2F92EE;'>#mCRPC#</a>, objectTitle=Lancet Oncol：mCRPC药物研究：找对评估标准方可获益更多, objectType=article, longId=92071, objectId=a7bc920e145, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7bc920e145, replyNumber=0, likeNumber=92, createdTime=2017-03-18, rootId=0, userName=liuquanmn, userId=d48314676153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7bc920e145, moduleTitle=Lancet Oncol：mCRPC药物研究：找对评估标准方可获益更多, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=a7bc920e145)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1555932, encodeId=51e21555932e3, content=<a href='/topic/show?id=641e1139ea8' target=_blank style='color:#2F92EE;'>#mCRPC#</a>, objectTitle=FDA：批准阿比特龙用于mCRPC一线解救治疗, objectType=article, longId=12978, objectId=0c31129e85f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c31129e85f, replyNumber=0, likeNumber=89, createdTime=2012-12-14, rootId=0, userName=liuquanmn, userId=d48314676153, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c31129e85f, moduleTitle=FDA：批准阿比特龙用于mCRPC一线解救治疗, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=0c31129e85f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

mCRPC

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#II期试验# #免疫检查点抑制剂# #mCRPC#

CLIN CANCER RES | 免疫检查点抑制剂治疗晚期转移性去势抵抗性前列腺癌的II期IMPACT试验

2024-05-29发表于上海

(审核中...)

前往app查看评论内容

#Ra-223#治疗的 #mCRPC#患者中，#骨代谢生物标志物# (BMB) 的预后价值。

Eur Urol Oncol：镭-223治疗转移去势抵抗性前列腺癌患者的骨代谢生物标志物和生存期的前瞻性评估： PRORADIUM研究

2023-10-24发表于上海

侠胆医心 (审核中...)

前往app查看评论内容

全文收起 #奥拉帕利#联合#阿比特龙#治疗#转移性去势抵抗性前列腺癌#（#mCRPC#）结果公布（#PROpel研究#），在放射学#无进展生存# (rPFS) 方面具有#统计学意义#和#临床意义#的改善显著，但是最近又报道了#生活质量#方面并没有变化，后续报道OS也没有统计学显著性区别，看来这也是一个隐忧，临床上值得不值得应用？

NEJM Evid：奥拉帕利联合阿比特龙治疗转移性前列腺癌结果公布（PROpel研究）

2023-10-10发表于上海

智智灵药 (审核中...)

前往app查看评论内容

#mCRPC#

Target Oncol:真实世界评估阿比特龙+泼尼松或泼尼松龙(AAP)一线或二线治疗转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性

2022-02-22

智智灵药 (审核中...)

前往app查看评论内容

#mCRPC#

Eur J Cancer：Nivolumab联合多西他赛治疗未经化疗的转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性

2021-12-04

智智灵药 (审核中...)

前往app查看评论内容

#mCRPC#

Lancet Oncol：阿帕鲁胺联合阿比特龙-泼尼松可明显改善mCRPC患者的生存预后

2021-10-07

智智灵药 (审核中...)

前往app查看评论内容

#mCRPC#

EU：评估哪些mCRPC患者更适合阿比特龙的模型

2021-09-26

智智灵药 (审核中...)

前往app查看评论内容

#mCRPC#

Clin Cancer Res：遗憾！阿特珠单抗+镭-223联合方案未能给mCRPC患者带来额外的临床效益

2021-09-06

智智灵药 (审核中...)

前往app查看评论内容

#mCRPC#

Eur J Cancer：耄耋之年mCRPC患者采用恩杂鲁胺治疗的效果优于醋酸阿比特龙

2021-06-22

智智灵药 (审核中...)

前往app查看评论内容

#mCRPC#

ASCO GU 2021：nmCRPC接受恩扎鲁胺治疗患者中PSA下降深度与生存结果密切相关（PROSPER试验）

2021-02-17

liuquanmn (审核中...)

前往app查看评论内容

#mCRPC#

Onvansertib能够克服Zytiga耐药性并为mCRPC患者提供临床益处

2020-02-16

liuquanmn (审核中...)

前往app查看评论内容

#mCRPC#

Trovagene在ASCO-GU会议上介绍了Onvansertib与Zytiga联合治疗mCRPC的II期研究

2019-02-20

liuquanmn (审核中...)

前往app查看评论内容

#mCRPC#

HPN424治疗转移性去势抵抗性前列腺癌（mCRPC）的I期临床试验

2018-08-09

liuquanmn (审核中...)

前往app查看评论内容

#mCRPC#

Eur Urol：mCRPC患者外周全血中的AR-V7预测治疗反应。

2017-08-26

liuquanmn (审核中...)

前往app查看评论内容

#mCRPC#

J Clin Oncol：巴他赛 vs 多西他赛一线治疗mCRPC 孰优孰劣？

2017-08-08

liuquanmn (审核中...)

前往app查看评论内容

#mCRPC#

J Clin Oncol:卡巴他赛 vs 多西他赛一线治疗mCRPC 孰优孰劣？

2017-08-08

liuquanmn (审核中...)

前往app查看评论内容

#mCRPC#

Lancet Oncol：mCRPC药物研究：找对评估标准方可获益更多

2017-03-18

liuquanmn (审核中...)

前往app查看评论内容

#mCRPC#

FDA：批准阿比特龙用于mCRPC一线解救治疗

2012-12-14

科室
- - 订阅+
  - 更多科室
工具
服务